VYNE Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
YARW$15.79+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The following documents are filed, or furnished as applicable, as part of this Quarterly Report on Form 10-Q:
Exhibit Index
| Exhibit Number · Incorporated by Reference · Filed | |||||
|---|---|---|---|---|---|
| Exhibit Description · Form · Date · Number · Herewith | |||||
| 3.1(a) | Amended and Restated Certificate of Incorporation. | 10-K | 3/17/2022 | 3.1 | |
| 3.1(b) | Certificate of Designation of Preferences, Rights, and Limitations of Series A Convertible Preferred Stock. | 10-Q | 11/14/2022 | 3.1(b) | |
| 3.1(c) | Certificate of Elimination | 8-K | 1/17/2023 | 3.1 | |
| 3.1(d) | Certificate of Amendment to the Amended and Restated Certificate of Incorporation. | 8-K | 2/10/2023 | 3.1 | |
| 3.2 | Amended and Restated Bylaws. | 10-Q | 11/14/2022 | 3.2 | |
| 10.1 | Sales Agreement, dated as of March 1, 2024, by and between VYNE Therapeutics Inc. and Cowen and Company, LLC. | 10-K | 3/1/2024 | 10.3 | |
| 31.1 | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 31.2 | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.1* | Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 32.2* | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | |||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | |||
| 101.SCH | XBRL Taxonomy Extension Schema Document. | X | |||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document. | X | |||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document. | X | |||
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document. | X | |||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document. | X |
| 104 | The cover page of VYNE Therapeutics Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline XBRL (included within Exhibit 101 attachments). |
- The certifications attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of VYNE Therapeutics Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.